BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28128193)

  • 21. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung.
    Ye J; Findeis-Hosey JJ; Yang Q; McMahon LA; Yao JL; Li F; Xu H
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):313-7. PubMed ID: 21464700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
    Zhang Y; Yang H; Qiu Y; Deng Q; Liu J; Zhao M; He P; Mo M; Zou X; He J
    Med Oncol; 2014 Mar; 31(3):803. PubMed ID: 24452282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IMP3 can predict aggressive behaviour of lung adenocarcinoma.
    Beljan Perak R; Durdov MG; Capkun V; Ivcevic V; Pavlovic A; Soljic V; Peric M
    Diagn Pathol; 2012 Nov; 7():165. PubMed ID: 23190601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.
    Piljić Burazer M; Mladinov S; Matana A; Kuret S; Bezić J; Glavina Durdov M
    Diagn Pathol; 2019 Sep; 14(1):105. PubMed ID: 31521181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas.
    Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F
    Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
    Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
    Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined detection of thyroid transcription factor 1 and napsin A in pleural fluid cell blocks facilitates cytopathologic diagnosis of pulmonary adenocarcinoma].
    Xu X; Liu H; Jiang H; Li C; Yuan S; Yang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1610-3. PubMed ID: 26607085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup.
    Yang X; Liu Y; Lian F; Guo L; Wen P; Liu XY; Lin DM
    Int J Clin Exp Pathol; 2014; 7(4):1459-68. PubMed ID: 24817941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
    Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M
    J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
    Sakai Y; Nakai T; Ohbayashi C; Imagawa N; Yanagita E; Satake R; Nitta A; Kajimoto K; Sakuma T; Itoh T
    Int J Surg Pathol; 2013 Oct; 21(5):476-82. PubMed ID: 23794492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma.
    Vaidya PJ; Kate AH; Mehta D; Dhabar BN; Chhajed PN
    J Cancer Res Ther; 2016; 12(2):1090-2. PubMed ID: 27461706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray.
    Sang M; Gu L; Yin D; Liu F; Lian Y; Zhang X; Liu S; Huang W; Wu Y; Shan B
    J Clin Pathol; 2017 Jun; 70(6):533-540. PubMed ID: 27864450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
    van Zyl A; Schubert PT; Koegelenberg CFN
    Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.
    Qu Y; Zhao D; Mu J; Che N; Zhang C; Liu Z; Su D; Zhou L; Zhang H; Wei L
    Tumour Biol; 2016 Jan; 37(1):887-96. PubMed ID: 26254613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.